In addition, we employ high throughput screening (HTS), cheminformatics, and medicinal chemistry of novel small molecule reagents that aid in
validating novel therapeutic approaches and in understanding the biology of signaling in the central nervous system.
The authors concluded that although the studies included in this review provided important information, double - blinded, sham - controlled phase II and phase III clinical trials with larger sample sizes are needed to
validate this novel therapeutic approach.